For research use only. Not for therapeutic Use.
An orally active cyclin-dependent kinase (CDK) inhibitor, specifically targeting on CDK4 and CDK6; a potential agent for the treatment of breast cancer; water soluble hydrochloride salt form, ideal for in vivo experiments. Another salt form, PD0332991 isethionate (Axon 2052) is also available.
Prime Source Information: The molecule of PD0332991 contains multiple basic nitrogens, which could form 1 to 4 eq HCl salt of PD0332991 and its accurate salt form has been determined by microanalysis and specified on certificate of analysis (COA) of every batch of our samples.
| Catalog Number | I047542 |
| CAS Number | 1831842-69-3 |
| Molecular Formula | C24H29N7O2.2HCl |
| Purity | ≥95% |
| IUPAC Name | 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one;dihydrochloride |
| InChI | InChI=1S/C24H29N7O2.2ClH/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32;;/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29);2*1H |
| SMILES | CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl.Cl |
| Reference | RL Sutherland and EA Musgrove. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res. 2009, 11(6), 112-113.
RS Finn et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11(5), R77.
D.W. Fry et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3, 1427-1438. |
